Adverse Drug Event Reporting - NAPLEX

Timeline, labs/vitals, comorbidities, concomitant meds, and outcome. Including these elements offers a comprehensive patient context, facilitating thorough evaluation of the event's causality and impact.

Drug name, strength, dose, route, lot number if known, and therapy dates. These details provide precise product identification and usage context, enhancing the report's value for causality assessment.

To support signal detection; suspected association is sufficient for reporting. Reporting suspicions aids in pharmacovigilance by contributing to data aggregation for detecting potential safety signals.

Ensure patient safety first, then document and report via institutional process and FDA if needed. Prioritizing patient safety addresses immediate risks, followed by documentation and reporting to prevent recurrence and ensure compliance.

Type B (bizarre). Type B reactions involve mechanisms unrelated to dose, such as hypersensitivity, rendering them unpredictable and rare.

Type A (augmented). Type A reactions arise from exaggerated normal pharmacological actions, making them predictable and often avoidable by dose adjustment.

Naranjo algorithm. The Naranjo algorithm uses a scoring system based on temporal association and other factors to estimate causality probability.

An adverse event or outcome description. Describing the adverse event fulfills ICH minimum criteria by providing the foundational details for safety evaluation.

A suspect product (drug, biologic, device, or vaccine). Identifying a suspect product is essential per ICH guidelines to link the event to a specific FDA-regulated item for analysis.

An identifiable reporter. Reporter identifiability allows for necessary follow-up inquiries to clarify or expand on the reported safety information.

An identifiable patient. Patient identifiability is a core ICH requirement to ensure report traceability and prevent duplicate entries in databases.

Not listed in the current labeling or not consistent with known specificity or severity. Unexpected events deviate from labeled information, prompting further investigation in postmarketing surveillance.

Patient was at immediate risk of death at the time of the event. This criterion emphasizes the immediacy of mortal risk during the event to classify it as requiring urgent reporting.

Death, life-threatening event, hospitalization, disability, anomaly, or intervention needed. FDA criteria for seriousness prioritize events with significant health impacts to expedite review and potential interventions.

MedWatch. MedWatch provides a centralized system for reporting issues with dietary supplements to support FDA regulatory oversight.

MedWatch (including Medical Device Reporting pathways). MedWatch integrates device reporting pathways to ensure systematic surveillance of medical device safety and performance.

VAERS (Vaccine Adverse Event Reporting System). VAERS, co-managed by FDA and CDC, specifically monitors vaccine safety to identify rare or unexpected adverse events.

FDA Form 3500A. Form 3500A is required for industry to comply with FDA regulations on reporting serious events and product issues.

FDA Form 3500. Form 3500 supports voluntary submissions to encourage widespread participation in pharmacovigilance without regulatory mandates.

MedWatch (FDA Safety Information and Adverse Event Reporting Program). MedWatch enables voluntary reporting by professionals to detect post-marketing safety signals for drugs and other products.

Any injury from medication use, including errors, ADRs, and overdoses. This broad definition captures all medication-related harms to facilitate comprehensive safety monitoring in healthcare settings.

Noxious, unintended response at normal doses for prophylaxis, diagnosis, or therapy. The WHO pharmacovigilance definition emphasizes harm occurring at standard therapeutic doses to distinguish from errors or overdoses.

ADE includes harm from errors; ADR is nonpreventable at normal doses. ADEs encompass both preventable and nonpreventable harms, while ADRs are limited to inherent drug risks at normal doses.

Obtain missing minimum element; if unobtainable, report with available information and note gaps. Attempting to complete minimum criteria ensures report validity, while noting gaps allows partial data to contribute to surveillance.